MNMarcin Noweta

Marcin Noweta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marcin Noweta has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Targeting Biomarkers of Proliferation and Inflammation (Ki67, p53, and COX-2) in Actinic Keratoses with Photodynamic Therapy

    by Justyna Ceryn, Aleksandra Lesiak, Magdalena Ciążyńska, Dorota Sobolewska-Sztychny, Marcin Noweta, Olga Stasikowska-Kanicka, Karol Ciążyński, Iris Zalaudek, Joanna Narbutt

    Background: Actinic keratoses (AKs) are common pre-neoplastic lesions that may progress to cutaneous squamous cell carcinoma (cSCC). Photodynamic therapy (PDT) is an effective field-directed treatment for AK, but its impact on key biomarkers remains unclear. This study evaluates the clinical, dermatoscopic, and immunohistochemical effects of PDT on AK, with a focus on proliferation (Ki67, p53) and inflammation (COX-2) markers, to assess its efficacy in delaying carcinogenesis. Methods: In our prospective one-center study, we enrolled 31 patients with AK, with no history of previous AK treatment. They underwent three PDT sessions at four-week intervals, with follow-up eight weeks after the final session. Clinical, dermatoscopic, and immunohistochemical analyses of Ki67, p53, and COX-2 expression were performed before and after treatment. Results: Clinically, 54.8% of patients achieved complete lesion clearance, with no residual severe AK lesions. Ki67 and p53 immunoexpression significantly decreased post-PDT (p < 0.05), confirming its antiproliferative effect. COX-2 expression also declined significantly (p < 0.05), supporting PDT’s anti-inflammatory role. However, COX-2 remained stable or increased in 35.48% of cases, possibly due to inflammation-induced regeneration. There is a positive correlation between the reduction in Ki67, p53, and COX-2 immunoexpression and the decrease in AK severity (both according to Olsen grade and dermatoscopic grade). Conclusions: PDT effectively reduces AK severity, proliferation, and inflammation markers, potentially delaying carcinogenesis. However, residual biomarker expression suggests that additional treatment sessions or combination therapies may be necessary for complete lesion clearance. Further studies are required to optimize PDT protocols.


  • Open Access

    Factors Influencing the Clinical Course of Bullous Pemphigoid among Geriatric Patients: A Pilot Study

    by Paula Mazan, Aleksandra Lesiak, Igor Bednarski, Dorota Sobolewska-Sztychny, Marcin Noweta, Joanna Narbutt

    Background and Objectives: Bullous pemphigoid (BP) is the most common autoimmune blistering disease affecting mainly elderly patients. Still, little is known about the pathogenesis of pruritus in BP or the factors that affect the clinical course of the disease. This study aimed to evaluate the factors influencing the clinical course of BP among older patients. Materials and Methods: A retrospective analysis of medical records of 55 patients with BP hospitalized in the dermatology department in 2015–2021 was conducted. The study focused on preliminary diagnosis, medical history, clinical examination (characteristics and location of cutaneous changes), laboratory investigation, and direct and indirect immunofluorescence. Results: Analysis of laboratory results in combination with the clinical course of BP showed that red blood cell count, hemoglobin, and hematocrit values were negatively associated with a risk of erosions and erythema, while MCHC values were positively correlated with a risk of associated pruritus. A correlation was found between neurological diseases and an increased risk of erosions. Conclusions: We have shown that age and neurological conditions, including stroke, affect the clinical course of BP. Further studies on a larger group of patients should be conducted to investigate the different factors affecting the clinical aspect of BP and to understand the relationship between them.


  • Open Access

    Analysis of access to treatment of patients with psoriatic arthritis within nationally founded treatment program B.35 “Treatment of active Psoriatic arthritis (PsA) (ICD-10 L 40.5, M 07.1, M 07.2, M 07.3)” in 2016–2021

    by Marcin Noweta, Joanna Narbutt, Aleksandra Lesiak

    Introduction: Psoriatic arthritis (PsA), is a chronic disease affecting women and men in equal measure. It is characterised by a diverse course, usually progressive and severe in 20% of patients. The symptoms develop progressively. In almost 75% of patients, skin symptoms precede joint symptoms, while 10–15% experience simultaneous symptoms in both skin and joints. The disease is characterised by a highly fluctuating course, with periods of exacerbation and remission. Funding for the treatment of patients with psoriatic arthritis with biological drugs is guaranteed under the B.35 drug programme. The analysis of the performance of this programme is the aim of this work. Material and methods: The statistical analysis was based on data published by the National Health Fund and the Ministry of Health. Results: Between 2016 and 2021, 8 active substances were funded under the B.35 drug programme, 4 of which were added in the last 6 years. The number of patients increased by 2087. The largest group of patients received care from physicians in the Małopolskie Voivodeship. The most common active substance used under the B.35 drug programme was adalimumab, while the highest annual increase in patients treated under the programme was observed for the drug secukinumab. The value of contracts for drugs increased by PLN 15.7 million, while the value of contracts for programme operations increased by PLN 3.7 million. The number of providers implementing this drug programme has increased by one. Conclusions: The B.35 drug programme is more substantial in terms of the number of patients treated and the value of funding than the B.47 (psoriasis) drug programme but smaller than the B.36 — ankylosing spondylitis (AS) drug programme implemented by rheumatologists. Virtually all drugs licensed for the treatment of moderate to severe psoriatic arthritis are currently reimbursed under the drug programme. Comparing epidemiological data in Poland and the number of patients in the drug programme, it should be pointed out that only about 1.8% of the total population of patients with PsA receives treatment. These very low values point to the need to further optimise the description of the drug programme or to transfer some drugs, for example, biosimilars, to outpatient health care. Introduction: Psoriatic arthritis (PsA), is a chronic disease affecting women and men in equal measure. It is characterised by a diverse course, usually progressive and severe in 20% of patients. The symptoms develop progressively. In almost 75% of patients, skin symptoms precede joint symptoms, while 10–15% experience simultaneous symptoms in both skin and joints. The disease is characterised by a highly fluctuating course, with periods of exacerbation and remission. Funding for the treatment of patients with psoriatic arthritis with biological drugs is guaranteed under the B.35 drug programme. The analysis of the performance of this programme is the aim of this work. Material and methods: The statistical analysis was based on data published by the National Health Fund and the Ministry of Health. Results: Between 2016 and 2021, 8 active substances were funded under the B.35 drug programme, 4 of which were added in the last 6 years. The number of patients increased by 2087. The largest group of patients received care from physicians in the Małopolskie Voivodeship. The most common active substance used under the B.35 drug programme was adalimumab, while the highest annual increase in patients treated under the programme was observed for the drug secukinumab. The value of contracts for drugs increased by PLN 15.7 million, while the value of contracts for programme operations increased by PLN 3.7 million. The number of providers implementing this drug programme has increased by one. Conclusions: The B.35 drug programme is more substantial in terms of the number of patients treated and the value of funding than the B.47 (psoriasis) drug programme but smaller than the B.36 — ankylosing spondylitis (AS) drug programme implemented by rheumatologists. Virtually all drugs licensed for the treatment of moderate to severe psoriatic arthritis are currently reimbursed under the drug programme. Comparing epidemiological data in Poland and the number of patients in the drug programme, it should be pointed out that only about 1.8% of the total population of patients with PsA receives treatment. These very low values point to the need to further optimise the description of the drug programme or to transfer some drugs, for example, biosimilars, to outpatient health care.

  • Open Access

    Risankizumab Therapy for Moderate-to-Severe Psoriasis—A Multi-Center, Long-Term, Real-Life Study from Poland

    by Michał Adamczyk, Joanna Bartosińska, Dorota Raczkiewicz, Kinga Adamska, Zygmunt Adamski, Maria Czubek, Beata Kręcisz, Elżbieta Kłujszo, Aleksandra Lesiak, Joanna Narbutt, et al.

    The present multi-center, long-term, real-life study made an attempt to assess the efficacy of risankizumab in the treatment of moderate-to-severe plaque psoriasis. The study comprised 185 patients from 10 Polish dermatologic departments undergoing risankizumab treatment. The disease severity was measured using the Psoriasis Area and Severity Index (PASI) before the start of the risankizumab treatment and next at the defined timepoints, i.e., 4, 16, 28, 40, 52 and 96 weeks of treatment. The percentage of patients achieving PASI90 and PASI100 responses as well as the PASI percentage decrease at the defined timepoints were calculated, and correlations with clinical characteristics and therapeutic effect were analyzed. The number of patients evaluated at the defined timepoints was: 136, 145, 100, 93, 62, and 22 at 4, 16, 28, 40, 52 and 96 weeks of treatment, respectively. At 4, 16, 28, 40, 52 and 96 weeks, the PASI90 response was achieved in 13.2%, 81.4%, 87.0%, 86.0%, 88.7% and 81.8% of patients, whereas the PASI100 response was achieved in 2.9%, 53.1%, 67.0%, 68.8%, 71.0% and 68.2% of patients, respectively. Our study revealed a significant negative correlation between a decrease in the PASI and the presence of psoriatic arthritis as well as the patient’s age and duration of psoriasis at several timepoints throughout the observation period.


  • Open Access

    Characteristic Features of Wound Dressings Based on Butyric-Acetic Chitin Copolyesters—Results of Clinical Trials

    by Ilona Latańska, Anna Kozera-Żywczyk, Elwira Beata Paluchowska, Witold Owczarek, Andrzej Kaszuba, Marcin Noweta, Józef Tazbir, Beata Kolesińska, Zbigniew Draczyński, Witold Sujka

    The article presents the results of clinical trials of wound dressings whose main ingredient is butyric-acetic chitin copolyester (BAC 90:10). It is a chitin derivative soluble in typical organic solvents. During the trial, the dressings were used on wounds resulting from venous insufficiency or diabetes. The trial evaluated the safety of use and efficacy of three forms of the dressing including porous membrane (Medisorb R Membrane), porous membrane with silver (Medisorb R Ag), and powder (Medisorb R Powder). The clinical trial had a multi-centre character. Three medical units were engaged in the study. The trial included 36 patients (12 men and 24 women). The mean age of the participants was 65 years of age (age range: 26–96). The choice of dressings was made on the basis of preliminary evaluation of the wound, clinical signs of infection, or risk of infection. Medisorb R Membrane dressing was used in 23 patients, Medisorb R Ag dressing was used in 15 patients, and Medisorb R powder was used in two patients. During the course of the trial, there were 10 control visits planned. The obtained results prove the safety and efficacy of dressings in question. The efficacy of treatment was evaluated as good. In the majority of patients, the ulceration was decreased both on the surface and in depth. The success of the treatment relied not only on the applied dressing, but also the stage of the basic disease, the accompanying diseases, and the age of the patient.


  • Open Access

    Malignant acanthosis nigricans associated with prostate cancer: a case report

    by Joanna Kubicka-Wołkowska, Sylwia Dębska-Szmich, Maja Lisik-Habib, Marcin Noweta, Piotr Potemski

    Acanthosis nigricans is characterized by hyperpigmentation and hyperkeratosis of the skin or mucous membranes. Its malignant form is associated with internal neoplasms, especially gastric adenocarcinoma (55–61%). Coexistence with prostate cancer is uncommon. In the paraneoplastic type of this dermatosis, the skin and mucous lesions are characteristically of more sudden onset and more severe than those in the benign form. The efficacy of various treatment strategies remains disappointing. We here report a case of 66-year-old Caucasian patient with metastatic prostate cancer and a mild form of acanthosis nigricans that preceded the diagnosis of malignancy and resolved with chemotherapy in parallel with the prostate cancer. The dermatosis recurred when the prostate cancer progressed. Concurrent acanthosis nigricans and prostate cancer is rare, and few such cases have been reported. Anti-tumor therapy occasionally results in regression of this dermatosis. Underlying malignant disease should be suspected in individuals with elderly-onset of acanthosis nigricans.